Less than two months after going public, Aquestive Therapeutics has hired a longtime Day Pitney partner as its new senior vice president and general counsel.
Lori Braender—who joined Day Pitney predecessor firm Pitney Hardin when she graduated from law school in 1983—will lead the legal functions for the Warren-based company, which is advancing a pipeline of treatment for central nervous system diseases.
Braender most recently chaired the firm’s life sciences practice group, advising health care clients on regulatory requirements, contractual arrangements and other business considerations, according to a Tuesday statement announcing her move.
The new GC could not be immediately reached for comment, but in the statement referenced Aquestive’s “unique business model and technology.”
Founded in 2004 as MonoSol Rx, Aquestive last July announced the closing of its roughly $60 million initial public offering. According to a report from Seeking Alpha, the company has two leading products: Libervant to treat epileptic and recurrent-convulsive seizures, and Sympazan, which treats seizures associated with Lennox-Gastaut syndrome, a form of severe epilepsy.
“With her knowledge and familiarity of the company, and the depth of her professional experience, Lori will be an important part of the leadership of Aquestive,” company CEO Keith Kendall said in the statement.
Braender graduated from Seton Hall University School of Law and Rider University, according to her LinkedIn profile.